IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding IN8BIO, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 30 | 32 | +2 |
| Shares | 8.58M | 8.64M | +58.1K (+0.7%) |
| Value | $11.4M | $10.2M | −$1.17M (−10.3%) |
New holders (6)
Institutions that held IN8BIO, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 32,557 | $38.4K | 0.00% |
| Wela Strategies, Inc. | 18,548 | $21.9K | 0.01% |
| Two Sigma Securities, LLC | 17,557 | $20.7K | 0.00% |
| Ground Swell Capital, LLC | 16,356 | $19.3K | 0.02% |
| Virtu Financial LLC | 14,044 | $17.0K | 0.00% |
| Goldman Sachs Group Inc | 11,612 | $13.7K | 0.00% |
Sold out (4)
Institutions that held IN8BIO, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Citadel Advisors LLC | 19,807 | $27.3K |
| HighTower Advisors, LLC | 10,000 | $14.0K |
| UBS Group AG | 4,505 | $6.22K |
| Bank of America Corp | 13 | $18 |